Clinical Trials on Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax in Hong Kong

Total 79 results

The University of Hong Kong

Recruiting

Roflumilast in Non-CF Bronchiectasis Study (2019)

Non-cystic Fibrosis Bronchiectasis

Hong Kong
The University of Hong Kong

Completed

Roflumilast in Non-CF Bronchiectasis Study

Non-cystic Fibrosis Bronchiectasis

Hong Kong
Gelb, Arthur F., M.D.
The Hospital for Sick Children; Stony Brook University; Miller Children's & Women...

Recruiting

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

Cystic Fibrosis in Children

United States
First Wave Bio, Inc.

Completed

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Cystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)

United States, Poland
First Wave Bio, Inc.

Completed

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (OPTION)

Cystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)

United States, Poland
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis

United States, Hungary, Israel, South Africa, Spain
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Cystic Fibrosis

United States, Canada
Chris Goss
Medical University of South Carolina; University of Washington; Cystic Fibrosis...

Recruiting

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)

Cystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation

United States, Canada
Novartis Pharmaceuticals

Completed

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

Cystic Fibrosis

United States
AbbVie
VIVUS LLC; Cystic Fibrosis Foundation; Digestive Care, Inc.; Nestle Health Science

Terminated

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Fibrosing Colonopathy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Chris Goss
Medical University of South Carolina; University of Washington; Cystic Fibrosis... and other collaborators

Completed

Standardized Treatment of Pulmonary Exacerbations II (STOP2)

Pulmonary Cystic Fibrosis

United States, Canada
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States
PTC Therapeutics

Terminated

Study of Ataluren (PTC124) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Spain, Belgium, Israel, Italy, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
University of Massachusetts, Worcester
Cystic Fibrosis Foundation

Completed

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis (DHA)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Aridis Pharmaceuticals, Inc.

Recruiting

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Cystic Fibrosis

United States
Calithera Biosciences, Inc

Completed

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated
Moderna, Inc

Recruiting

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, United Kingdom, Australia, Canada
Corbus Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Cystic Fibrosis

Belgium, United States, United Kingdom, Italy, France, Germany, Poland
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden, United Kingdom
PTC Therapeutics
Cystic Fibrosis Foundation; ECFS-Clinical Trial Network (ECFS-CTN)

Completed

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Cystic Fibrosis

United States, Spain, United Kingdom, Netherlands, Germany, France, Belgium, Italy, Australia, Argentina, Brazil, Bulgaria, Canada, Greece, Israel, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Seattle Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center

Completed

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Study of Ataluren (PTC124™) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, United Kingdom, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
AbbVie
Janssen Research & Development, LLC; Forest Laboratories

Completed

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Cystic Fibrosis

United States
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD)

Cystic Fibrosis

United States, Australia, Canada
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
PTC Therapeutics

Terminated

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Cystic Fibrosis

United States, Spain, France, Belgium, United Kingdom, Australia, Brazil, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Argentina, Greece
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Humanigen, Inc.

Completed

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (KB001-A)

Cystic Fibrosis

United States, Australia, Israel, New Zealand
Gilead Sciences

Completed

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF1)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden

Clinical Trials on Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations